Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | LTK | P29376 | 1/20 | 0.55 |
| ▸ | GRK5 | P34947 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.55 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.55 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 17/20 | 0.49 |
| ▸ | JAK2 | O60674 | 16/20 | 0.49 |
| ▸ | AURKA | O14965 | 2/20 | 0.49 |
| ▸ | PRKCA | P17252 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23408965 | 0.83 | PIK3CA (0.62) | JAK3RETFGFR1LTKGRK5 | |
| SCHEMBL25068859 | 0.82 | JAK1 (0.54) | JAK3RETFGFR1LTKGRK5 | |
| SCHEMBL17122716 | 0.82 | JAK3 (0.58) | JAK3RETFGFR1LTKGRK5 | |
| SCHEMBL12032395 | 0.81 | JAK3 (0.64) | JAK3RETFGFR1LTKGRK5 | |
| SCHEMBL20290048 | 0.79 | JAK3 (0.53) | JAK3RETFGFR1LTKGRK5 | |
| SCHEMBL18855755 | 0.78 | JAK1 (0.61) | JAK3RETFGFR1LTKGRK5 | |
| SCHEMBL20289826 | 0.77 | JAK1 (0.56) | JAK3RETFGFR1LTKGRK5 | |
| SCHEMBL24642393 | 0.76 | JAK1 (0.60) | JAK3RETFGFR1LTKGRK5 | |
| SCHEMBL20283630 | 0.75 | JAK3 (0.55) | JAK3RETFGFR1LTKGRK5 | |
| SCHEMBL20289718 | 0.75 | JAK3 (0.58) | JAK3RETFGFR1LTKGRK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017539-A1 | TRI-HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017539-A1 | TRI-HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND USE THEREOF | JAK2, JAK1, JAK3 | JAK3 3/4885RET 119/4885FGFR1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.